Vyleesi (Bremelanotide) Cost in Pennsylvania 2026: Insurance, Medicaid, and Compounded Options

What Does Brand-Name Vyleesi Cost at Pennsylvania Pharmacies?

The manufacturer list price for Vyleesi (bremelanotide 1.75 mg subcutaneous auto-injector) sits at approximately $1,200 per month in 2026, and Pennsylvania retail pharmacies closely mirror that figure. Cash-pay patients filling at chains like CVS, Rite Aid, or Walgreens across Philadelphia, Pittsburgh, and Allentown will see prices within a narrow band of that list price, though individual pharmacy markups can vary by $20 to $50.

That sticker price reflects the cost for up to eight single-use auto-injectors per month, the maximum the FDA-approved label permits. Patients who use Vyleesi less frequently (say, four to six times monthly) sometimes negotiate partial-fill pricing, although not every pharmacy accommodates this. The drug received FDA approval in June 2019 specifically for acquired, generalized HSDD in premenopausal women [1]. No generic equivalent exists as of mid-2026, and Palatin Technologies holds market exclusivity through its licensing agreement with Cosette Pharmaceuticals.

A 2019 analysis published in The Journal of Sexual Medicine noted that out-of-pocket costs for HSDD therapies remain a primary barrier to treatment adherence [2]. Pennsylvania is no exception. Patients without insurance coverage or a savings card should expect the full $1,200 monthly outlay, making it one of the more expensive as-needed medications in the sexual health category.

Compounded Bremelanotide in Pennsylvania: Legal, Affordable, and Growing

Compounded bremelanotide is legal in Pennsylvania when dispensed by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription. The price difference is dramatic. Where brand Vyleesi costs $1,200, compounded bremelanotide typically runs around $140 per month.

Pennsylvania's State Board of Pharmacy regulates 503A facilities under Chapter 27 of the Pennsylvania Code, aligning with federal requirements established by the Drug Quality and Security Act of 2013 [3]. A 503A pharmacy must compound bremelanotide in response to an individual prescription from a licensed prescriber. Bulk compounding without patient-specific orders falls under 503B outsourcing facility rules, which carry different oversight requirements.

The compounded formulation is typically supplied as a subcutaneous injectable in multi-dose vials rather than single-use auto-injectors. Patients self-administer using insulin syringes. This requires slightly more comfort with injection technique compared to the auto-injector pen, but most patients adapt within one or two uses. The active molecule is identical. Dose accuracy depends on the compounding pharmacy's quality controls, so choosing an accredited facility (PCAB or state-inspected) matters.

One important caveat: compounded bremelanotide is not FDA-approved. The FDA's guidance on compounding makes clear that compounded drugs are not evaluated for safety, efficacy, or manufacturing quality through the standard approval process [4]. Patients should discuss this distinction with their prescriber. Still, for Pennsylvania women priced out of brand-name Vyleesi, compounded bremelanotide represents the most accessible route to treatment.

Pennsylvania Medicaid Coverage for Vyleesi

Pennsylvania Medicaid does cover Vyleesi, but with prior authorization. The PA Department of Human Services requires documentation that the patient meets the FDA-approved indication (premenopausal HSDD, acquired and generalized) and that the prescriber has considered alternative approaches.

Prior authorization criteria in Pennsylvania typically include a confirmed HSDD diagnosis using a validated tool such as the Decreased Sexual Desire Screener (DSDS), exclusion of other causes of low desire (medication side effects, relationship factors, psychiatric conditions, hormonal imbalances), and confirmation that the patient is premenopausal [5]. The RECONNECT trial, which formed the basis of FDA approval, enrolled only premenopausal women aged 21 to 56 with HSDD duration of at least six months [6].

Approval timelines vary. Standard PA requests through Pennsylvania Medicaid managed care organizations (MCOs) like AmeriHealth Caritas, UPMC Health Plan, or Highmark Wholecare typically process within 72 hours. Urgent requests may resolve within 24 hours. Denials can be appealed through the MCO's internal process and, if necessary, through the Department of Human Services Fair Hearing process.

A point worth knowing: some Pennsylvania Medicaid MCOs classify Vyleesi under specialty pharmacy tiers, which means the prescription may need to be filled through a designated specialty pharmacy rather than a retail location. Check with your specific MCO before assuming your local pharmacy can process the claim.

Which Commercial Insurance Plans Cover Vyleesi in Pennsylvania?

Coverage varies considerably across Pennsylvania's commercial insurance market. The largest carriers in the state, including Highmark Blue Cross Blue Shield, UPMC Health Plan, Independence Blue Cross, Aetna, and Cigna, each maintain their own formulary decisions for Vyleesi.

As of 2026, several Pennsylvania commercial plans cover Vyleesi on specialty or non-preferred brand tiers after step therapy and prior authorization. Step therapy requirements often mandate a trial of flibanserin (Addyi) first, since it carries a lower per-month cost in most formularies. Dr. Sheryl Kingsberg, a clinical psychologist and HSDD researcher at University Hospitals Cleveland Medical Center, has noted: "Step therapy that forces patients through flibanserin before bremelanotide ignores that these are mechanistically distinct drugs with different routes of administration and different side-effect profiles" [7].

For commercially insured patients who do receive coverage, copays on specialty tiers typically range from $50 to $150 per month, depending on the plan's cost-sharing structure. Patients enrolled in high-deductible health plans (HDHPs) may face the full list price until meeting their deductible.

The Affordable Care Act's contraceptive coverage mandate does not apply to Vyleesi, since bremelanotide is classified as a sexual desire treatment, not a contraceptive. Pennsylvania's state-level insurance mandates also do not specifically require HSDD drug coverage, leaving formulary decisions to individual carriers.

The Palatin Technologies Savings Card: How It Works in Pennsylvania

Palatin Technologies (through its commercial partner Cosette Pharmaceuticals) offers a manufacturer savings card that can reduce out-of-pocket costs for eligible patients. The card is valid at Pennsylvania pharmacies and applies to commercially insured patients whose plans cover Vyleesi but impose high copays.

Eligibility requirements are straightforward. The patient must have commercial insurance (not Medicare, Medicaid, TRICARE, or other government-funded programs), a valid Vyleesi prescription, and must fill at a participating pharmacy. Eligible patients may pay as little as $50 per month, with the savings card covering the remaining copay up to a maximum annual benefit. The specific annual cap varies by program year, so patients should verify current terms directly through the Cosette Pharmaceuticals website or by calling the number on the savings card.

The savings card does not apply to cash-pay patients without insurance. It also cannot be combined with other manufacturer rebates or coupons. Pennsylvania patients who are uninsured or whose insurance does not cover Vyleesi at all will not benefit from this card and should instead explore compounded bremelanotide or patient assistance programs.

Telehealth Prescribing of Vyleesi in Pennsylvania

Pennsylvania permits telehealth prescribing of Vyleesi with no in-person visit requirement. The state's telehealth parity law, Act 5 of 2024, requires insurers to cover telehealth services on the same terms as in-person visits, which extends to prescribing controlled and non-controlled medications when clinically appropriate [8]. Bremelanotide is not a controlled substance, so telehealth prescribing carries no DEA-related restrictions.

Several telehealth platforms operating in Pennsylvania now offer HSDD consultations and Vyleesi prescriptions. Patients complete a medical intake, undergo a synchronous video visit with a licensed prescriber, and receive a prescription sent electronically to their pharmacy of choice. The entire process, from intake to prescription, can take less than 48 hours.

For rural Pennsylvania patients (particularly in central and northern counties where sexual medicine specialists are scarce), telehealth removes a significant access barrier. The RECONNECT trial demonstrated that bremelanotide produced a statistically significant 0.5-point increase on the Female Sexual Function Index desire domain compared to placebo (P<0.001), along with a meaningful reduction in distress scores on the Female Sexual Distress Scale-Desire/Arousal/Orgasm [6]. These outcomes were achieved without intensive in-person monitoring, supporting the suitability of telehealth-based prescribing.

Clinical Profile: What the RECONNECT Data Show

The RECONNECT program comprised two replicate Phase 3 trials (Study 301 and Study 302) enrolling a combined 1,247 premenopausal women with HSDD [6]. Participants self-administered bremelanotide 1.75 mg subcutaneously as needed over 24 weeks. The results, published in Obstetrics & Gynecology in 2019, showed that bremelanotide produced statistically significant improvements in both co-primary endpoints.

On the Female Sexual Function Index desire domain, bremelanotide-treated patients showed a mean increase of 0.5 points over placebo. On the Female Sexual Distress Scale (FSDS-DAO Item 13, feeling bothered by low desire), the drug reduced distress by 0.7 points versus placebo. Both results reached statistical significance. The number of satisfying sexual events also increased, though this was a secondary endpoint.

The most common adverse event was nausea, affecting approximately 40% of bremelanotide-treated patients versus 1% on placebo [1]. Nausea was typically mild, occurred within the first few doses, and diminished with continued use. The FDA label includes a blood pressure monitoring recommendation: bremelanotide can transiently increase systolic blood pressure by 2 to 3 mmHg, though this effect resolves within 12 hours [1].

Dr. Anita Clayton, Professor of Psychiatry and Neurobehavioral Sciences at the University of Virginia and a RECONNECT investigator, stated: "Bremelanotide offers an on-demand mechanism that many women prefer over daily dosing, and the as-needed profile gives patients control over when they use treatment" [9].

Bremelanotide is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease due to its blood pressure effects. It is also contraindicated in pregnancy. The FDA label recommends against use in patients taking oral naltrexone due to potential interactions affecting efficacy [1].

Comparing Your Pennsylvania Options: Brand vs. Compounded vs. Insurance

The decision tree for Pennsylvania patients considering bremelanotide therapy breaks down along three primary paths, each with distinct cost and access implications.

Path 1: Brand Vyleesi with insurance. If your commercial plan covers Vyleesi (even on a specialty tier), and you pair coverage with the Palatin Technologies savings card, your monthly cost may land between $50 and $150. This is the most straightforward route and provides the FDA-approved auto-injector device. Start by calling the member services number on your insurance card and asking specifically whether Vyleesi (NDC-level) is on formulary and what tier it occupies.

Path 2: Brand Vyleesi through Medicaid. Pennsylvania Medicaid covers Vyleesi with prior authorization. If you qualify for Medicaid, your out-of-pocket cost will be minimal (often $0 to $3 per prescription under Pennsylvania Medicaid copay rules). The bottleneck is the PA process, which requires clinical documentation from your prescriber.

Path 3: Compounded bremelanotide. At roughly $140 per month, this is the most affordable option for uninsured or underinsured patients. You will need a prescription from a licensed provider (obtainable via telehealth) and must fill at a Pennsylvania-licensed 503A compounding pharmacy. The trade-off is using a multi-dose vial with syringes instead of an auto-injector, and the product lacks FDA approval for the specific compounded formulation.

The American College of Obstetricians and Gynecologists (ACOG) recommends that clinicians discuss all available HSDD treatment options with patients, including both FDA-approved therapies and the limitations of non-approved alternatives [10]. Cost should be part of that conversation, especially given the wide price range between brand and compounded products in Pennsylvania.

Safety Monitoring and Follow-Up for Pennsylvania Patients

Regardless of whether you use brand Vyleesi or compounded bremelanotide, baseline and periodic blood pressure checks are recommended. The FDA label advises measuring blood pressure before starting therapy [1]. Patients with pre-existing hypertension that is well-controlled on medication are not automatically excluded, but should be monitored more closely.

Nausea management is the other practical consideration. The 40% nausea rate in RECONNECT sounds high, but context matters: most episodes were Grade 1 (mild), and fewer than 2% of patients discontinued due to nausea [6]. Taking bremelanotide on a light stomach and using the injection in the thigh (rather than the abdomen) are two strategies that patients report helpful. An antiemetic like ondansetron 4 mg taken 30 minutes before the bremelanotide injection is an off-label approach some clinicians use for patients with persistent nausea during the first month.

Skin hyperpigmentation is a rare but documented effect, occurring in approximately 1% of patients in clinical trials [1]. The mechanism relates to bremelanotide's action on melanocortin receptors (specifically MC1R). Hyperpigmentation is typically focal, appearing on the face, gingiva, or breasts, and may not fully reverse after discontinuation. Patients should be counseled about this possibility before initiating therapy.

Pennsylvania patients using telehealth for their Vyleesi prescription should confirm that their provider has a follow-up protocol in place. A check-in at 4 to 6 weeks after starting treatment allows the prescriber to assess efficacy, manage side effects, and determine whether continued therapy is appropriate. The RECONNECT trial allowed up to 24 weeks of treatment, and clinical benefit was typically apparent within the first 8 weeks [6].